This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Unmet Need in Multiple MyelomaMode of ActionAboutReimbursement InformationStudy OverviewStudy Design and Baseline DemographicsEfficacy OutcomesFollow-up Analyses OutcomesSafety ProfileMagnetisMM-3 StudySafetyDosingMaterialsVideosEventsSupport & Resources

The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.

NOW APPROVED for the treatment of relapsed or refractory multiple myeloma (RRMM)
ELREXFIO® (elranatamab) has a conditional marketing authorisation. A conditional marketing authorisation means that further evidence of efficacy and safety data are being collected. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year.
The licensing authority will review new information on this medicine at least every year and update the Summary of Product Characteristics as necessary.
Introducing ELREXFIO®(elranatamab), a BCMA-directed bispecific immunotherapy1NOW APPROVED for the treatment of relapsed or refractory multiple myeloma (RRMM)
ELREXFIO® is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.2
Mode of Action ELREXFIO® is a BCMA-CD3-directed bispecific antibody that activates a tumour-specific immune response1 See more LoadingDosing A single-use vial supplied as a ready-to-use solution that does not need dilution prior to administration, designed for subcutaneous injection1 Learn more LoadingClinical Trials In the Phase 2 MagnetisMM-3 trial, ELREXFIO® delivered deep and durable responses in some BCMA-directed therapy-naïve patients (n=123), and demonstrated a generally manageable safety profile*†1,3 Explore the dataLoadingSafety ProfileAdverse event information from a database of patients receiving ELREXFIO® at the recommended full treatment dose, including 183 patients from the MagnetisMM-3 study1 Learn moreLoading
*Deep response defined as ≥CR.2  †As assessed by BICR.1BCMA: B-cell maturation antigen; CD3: cluster of differentiation 3; CD38: cluster of differentiation 38.References:ELREXFIO® Summary of Product Characteristics. Click here for Great Britain. Click here for Northern Ireland.Kumar S, et al. Lancet Oncol. 2016;17:e328-e346.Lesohkin AM, et al. Nat Med. 2023;29(9):2259-2267.
PP-L1A-GBR-0506. November 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​